Colesevelam HCl: a non-systemic lipidaltering drug
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Colesevelam HCl (WelChol, Sankyo Pharmaceuticals Inc.) is a bile acid sequestrant polymer, which has been shown to significantly lower low density lipoprotein cholesterol and favourably affect high-density lipoprotein cholesterol blood levels in monotherapy and in combination with statins (HMG-CoA reductase inhibitors). Although it is similar to other bile acid sequestrants in that it binds bile acids and is non-systemic, colesevelam HCl differs in that it has a unique polymer structure that allows for greater tolerability with less potential drug interactions than with resins. Currently, statins are the most commonly prescribed lipid-altering drugs. However, it is not uncommon that patients demonstrate true or perceived intolerances to statin therapy, that are often dose-related and may include elevations in liver or muscle enzyme blood levels, or myalgias or muscle weakness without muscle enzyme elevation. In rare circumstances, myopathy and even rhabdomyolysis can occur with statins. In addition, many statins also have important potential drug interactions. Finally, statin monotherapy is often not sufficient in achieving lipid treatment goals in many severely dyslipidaemic patients and the availability of colesevelam HCl provides a lipid-altering treatment addition to other lipid-altering drugs. From a clinical perspective, such combination therapy is often required to achieve treatment goals [1] in patients with more complicated or severe dyslipidaemia. Colesevelam HCl may also be an alternative in monotherapy for many patients with mild-to-moderate hypercholesterolaemia, as well as in some patients at potential risk from systemic exposure to alternative lipid-altering drugs (such as young children and fertile women).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979 · cited 1×
“In addition to monotherapy, other clinical trials have demonstrated the efficacy of bile acid sequestrants, not only in improving lipid blood levels but also in significantly reducing relative CHD events, when combined with other lipid-altering drugs such as niacin [4-6] and niacin plus lovastastin [7].”
BackgroundThompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Dietschy, J., Turley, S., & Spady, D. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)35728-x · Cited by 874
Statin-associated myopathy with normal creatine kinase levels
Phillips, P. S., Haas, R. H., Bannykh, S., Hathaway, S., Gray, N. L., Kimura, B. J., Vladutiu, G. D., England, J. D. F., & and the Scripps Mercy Clinical Research Center* (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-7-200210010-00009 · Cited by 565
Cited by
Clinical Utility of Bile Acid Sequestrants in the Treatment of Dyslipidemia: A Scientific Review
Insull, W. (2006) · Southern Medical Journal · doi:10.1097/01.smj.0000208120.73327.db · Cited by 308
Statin Safety: An Overview and Assessment of the Data—2005
Bays, H. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.006 · Cited by 264
Self-citationRoss, S., D’Mello, M., Anand, S. S., Eikelboom, J., CARDIoGRAMplusC4D Consortium*, Stewart, A. F. R., Samani, N. J., Roberts, R., & Paré, G. (2015) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.114.000952 · Cited by 90
“This leads to an increase in bile acid synthesis and a subsequent decrease in plasma LDL-C levels.(51) Animal models have demonstrated that hepatic ABCG5/8 transporters are responsible for secreting multiple sterols in the bile, whereas intestinal transporters limit cholesterol absorption from the lumen and thus promo…”
BackgroundThe 'forgotten' bile acid sequestrants: is now a good time to remember?
Bays, H. E., & Goldberg, R. B. (2007) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31815a69fc · Cited by 83
“The increase in cholesterol catabolism to bile acids results in a compensatory increase in hepatic LDL receptor activity, clearing LDL-C from the circulation and thus reduces LDL-C levels.(48) Improvement in peripheral cholesterol transport may be another lipid benefit of BAS.”
BackgroundResultInfluentialSelf-citationColesevelam for type 2 diabetes mellitus: an abridged Cochrane review
Ooi, C. P., & Loke, S. C. (2014) · Diabetic Medicine · doi:10.1111/dme.12295 · Cited by 39
Metadata
- Authors
- Bays, H., & Dujovne, C.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2003-05
- Volume
- 4
- Issue
- 5
- Pages
- 779-790
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2062679938
- Cited by
- 98
- References
- 4
- FWCI
- 5.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Colesevelam HCl: a non-systemic lipidaltering drug. https://app.cochat.ai/papers/10.1517/14656566.4.5.779
- The paper
- Bays, H., & Dujovne, C. (2003). Colesevelam HCl: a non-systemic lipidaltering drug. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656566.4.5.779
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.